Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Saturday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

NYSE:BTX opened at $0.43 on Friday. The stock has a 50-day simple moving average of $0.94 and a 200 day simple moving average of $1.51. Brooklyn ImmunoTherapeutics has a one year low of $0.17 and a one year high of $10.10. The company has a market capitalization of $25.30 million, a price-to-earnings ratio of -0.19 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.